Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Mass General Brigham

Status and phase: Terminated; Early Phase 1

Conditions: Subarachnoid Hemorrhage

Treatments: Drug: placebo; Drug: desferrioxamine (DFO)

Study type: Interventional

Funder types: Other

Identifiers

NCT02216513

2014P001400

Details and patient eligibility

About

The investigators will test the central hypothesis that DFO treatment after SAH may improve cerebrovascular regulation, mitigate ischemic neural injury, and serve as an effective neuroprotectant against delayed ischemic injury after SAH.

Enrollment: 2 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of spontaneous SAH
• impaired cerebral autoregulation on day 2-4 post SAH

Exclusion criteria

• traumatic SAH
• other central neurological disorders such as tumors, known prior stroke, hemorrhage or vascular malformations
• pregnancy
• severe renal disease or anuria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

2 participants in 2 patient groups, including a placebo group

Desferrioxamine (DFO)

Active Comparator group

Description:

DFO (20mg/kg/hr) in normal saline IV for 4 hours for 5 consecutive days

Treatment:

Drug: desferrioxamine (DFO)

placebo

Placebo Comparator group

Description:

normal saline IV for 4 hours for 5 consecutive days

Treatment:

Drug: placebo